<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We describe the occurrence of myelodysplastic changes (hypogranular myeloid series and Pelger cells, dyserythropoiesis with ring sideroblasts) in five of 31 patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> after treatment with <z:chebi fb="0" ids="35584">purine</z:chebi> analogues </plain></SENT>
<SENT sid="1" pm="."><plain>The bone marrows of 31 patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> before and after treatment with <z:chebi fb="0" ids="35584">purine</z:chebi> analogues were reviewed </plain></SENT>
<SENT sid="2" pm="."><plain>The majority of patients had received extensive prior treatment, but none had dysplastic changes prior to treatment with <z:chebi fb="0" ids="35584">purine</z:chebi> analogues </plain></SENT>
<SENT sid="3" pm="."><plain>We suggest that a <z:chebi fb="0" ids="35584">purine</z:chebi> analogue may have been responsible for dysplastic change and that further follow-up of this phenomenon is warranted </plain></SENT>
</text></document>